Market Research Logo

Premature Labor (Tocolysis) - Pipeline Review, H2 2016

Premature Labor (Tocolysis) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Premature Labor (Tocolysis) - Pipeline Review, H2 2016’, provides an overview of the Premature Labor (Tocolysis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)
    • The report reviews pipeline therapeutics for Premature Labor (Tocolysis) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Premature Labor (Tocolysis) therapeutics and enlists all their major and minor projects
    • The report assesses Premature Labor (Tocolysis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Premature Labor (Tocolysis) Overview
    Therapeutics Development
    Pipeline Products for Premature Labor (Tocolysis) - Overview
    Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis
    Premature Labor (Tocolysis) - Therapeutics under Development by Companies
    Premature Labor (Tocolysis) - Therapeutics under Investigation by Universities/Institutes
    Premature Labor (Tocolysis) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Premature Labor (Tocolysis) - Products under Development by Companies
    Premature Labor (Tocolysis) - Products under Investigation by Universities/Institutes
    Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
    AMAG Pharmaceuticals, Inc.
    GlaxoSmithKline Plc
    Juniper Pharmaceuticals, Inc.
    Kissei Pharmaceutical Co., Ltd.
    Lipocine Inc.
    ObsEva SA
    Premature Labor (Tocolysis) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    bedoradrine sulfate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    hydroxyprogesterone caproate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    hydroxyprogesterone caproate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OBE-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OBE-022 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    progesterone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    retosiban - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Acute Inflammation and Premature Labor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Premature Labor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Premature Labor (Tocolysis) - Dormant Projects
    Premature Labor (Tocolysis) - Discontinued Products
    Premature Labor (Tocolysis) - Product Development Milestones
    Featured News & Press Releases
    Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor
    Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
    Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
    Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women
    Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301
    Nov 23, 2015: AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena
    Nov 18, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena (hydroxyprogesterone caproate injection)
    Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor
    Sep 01, 2015: ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways
    Jun 23, 2015: ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study - Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women
    May 28, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena
    May 20, 2015: AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth
    Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour
    Feb 26, 2015: ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour
    Jul 02, 2012: FDA Issues Further Guidance On K-V Pharma's Makena
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Premature Labor (Tocolysis), H2 2016
    Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Premature Labor (Tocolysis) - Pipeline by AMAG Pharmaceuticals, Inc., H2 2016
    Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H2 2016
    Premature Labor (Tocolysis) - Pipeline by Juniper Pharmaceuticals, Inc., H2 2016
    Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
    Premature Labor (Tocolysis) - Pipeline by Lipocine Inc., H2 2016
    Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Premature Labor (Tocolysis) - Dormant Projects, H2 2016
    Premature Labor (Tocolysis) - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Premature Labor (Tocolysis), H2 2016
    Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report